Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

NCT00139776 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

875

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions

DRUG: Celecoxib
DRUG: Celecoxib

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.